WTWen-Jie Tang

Wen-Jie Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wen-Jie Tang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Dan Li

    Digestive Department, Union Hospital of Fujian Medical University , Fuzhou 350001, China

    1 shared publication
  • Jian Ding

    Department of Gastroenterology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, People’s Republic of China

    1 shared publication
  • Kai Wang

    Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China

    1 shared publication
  • Xiaofei Liang

    State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, No. 25/Ln 2200 Xie Tu Road, Shanghai, 200032, China

    1 shared publication
  • Ying Lu

    Research Centre for Translational Medicine, East Hospital, Tongji University School of Medicine , 150 Jimo Road, Shanghai 200120, China

    1 shared publication
  • You-Zhen Wei

    Research Centre for Translational Medicine, East Hospital, Tongji University School of Medicine , 150 Jimo Road, Shanghai 200120, China

    1 shared publication

Latest Publications

  • Open Access

    Construction of Epidermal Growth Factor Receptor Peptide Magnetic Nanovesicles with Lipid Bilayers for Enhanced Capture of Liver Cancer Circulating Tumor Cells

    by Jian Ding, Kai Wang, Wen-Jie Tang, Dan Li, You-Zhen Wei, Ying Lu, Zong-Hai Li, Xiao-Fei Liang

    Highly effective targeted tumor recognition via vectors is crucial for cancer detection. In contrast to antibodies and proteins, peptides are direct targeting ligands with a low molecular weight. In the present study, a peptide magnetic nanovector platform containing a lipid bilayer was designed using a peptide amphiphile (PA) as a skeleton material in a controlled manner without surface modification. Fluorescein isothiocyanate-labeled epidermal growth factor receptor (EGFR) peptide nanoparticles (NPs) could specifically bind to EGFR-positive liver tumor cells. EGFR peptide magnetic vesicles (EPMVs) could efficiently recognize and separate hepatoma carcinoma cells from cell solutions and treated blood samples (ratio of magnetic EPMVs versus anti-EpCAM NPs: 3.5 ± 0.29). Analysis of the circulating tumor cell (CTC) count in blood samples from 32 patients with liver cancer showed that EPMVs could be effectively applied for CTC capture. Thus, this nanoscale, targeted cargo-packaging technology may be useful for designing cancer diagnostic systems.